Liu Ping, Yang Ping, Zhang Lan
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs, Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing 100053, China.
Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563000, China.
Evid Based Complement Alternat Med. 2020 Nov 22;2020:8838888. doi: 10.1155/2020/8838888. eCollection 2020.
Although the traditional Chinese medicine Shan-Zhu-Yu may be efficacious against depression, its mechanism of action is unknown. In this study, we aimed to explore the possible mechanisms of action of Shan-Zhu-Yu in the treatment of depression using network pharmacology.
The active ingredients and targets of Shan-Zhu-Yu were obtained from the Traditional Chinese Medicine System Pharmacology Database (TCMSP) database and converted into gene names using UniProt. Then, the target genes of depression were collected using GeneCards and OMIM. Drug disease intersection genes were obtained using a Venn tool, and a protein-protein interaction network was constructed using STRING. Cytoscape was used to construct an active ingredients-targets-drug-disease network. GO and KEGG pathway enrichment analyses were performed using DAVID. Furthermore, Autodock was used to evaluate drug and target binding and explore possible molecular mechanisms.
We identified 9721 disease genes, 13 active ingredients, 50 target genes, and 48 drug disease intersecting genes. The results of the GO enrichment analysis suggested that Shan-Zhu-Yu affects the activity of G protein-coupled amine, neurotransmitter, steroid hormone, nuclear, and G protein-coupled neurotransmitter receptors in the treatment of depression by acting on hormone and nuclear receptor binding. The main signaling pathways were associated with neuroactive ligand-receptor interaction, calcium, cGMP-PKG, apoptosis, estrogen, p53, and AGE-RAGE. Molecular docking confirmed that the active components of Shan-Zhu-Yu (e.g., telocinobufagin and -sitosterol) docked suitably with , , , and . Shan-Zhu-Yu may exert its therapeutic effects on depression via multiple targets and pathways.
The present study elucidates that Shan-Zhu-Yu suppresses the expression of and and promotes that of and through neuroactive ligand-receptor interaction and apoptosis signaling pathways. Therefore, Shan-Zhu-Yu is a potential treatment option for depression, and the results of this study will provide new reference points for future experimental research and a scientific basis for its widespread clinical application.
尽管中药山茱萸可能对抑郁症有效,但其作用机制尚不清楚。在本研究中,我们旨在使用网络药理学探索山茱萸治疗抑郁症的可能作用机制。
从中药系统药理学数据库(TCMSP)数据库中获取山茱萸的活性成分和靶点,并使用UniProt将其转换为基因名称。然后,使用GeneCards和OMIM收集抑郁症的靶基因。使用Venn工具获得药物-疾病交集基因,并使用STRING构建蛋白质-蛋白质相互作用网络。使用Cytoscape构建活性成分-靶点-药物-疾病网络。使用DAVID进行GO和KEGG通路富集分析。此外,使用Autodock评估药物与靶点的结合,并探索可能的分子机制。
我们鉴定出9721个疾病基因、13种活性成分、50个靶基因和48个药物-疾病交集基因。GO富集分析结果表明,山茱萸通过作用于激素和核受体结合,在治疗抑郁症时影响G蛋白偶联胺、神经递质、类固醇激素、核和G蛋白偶联神经递质受体的活性。主要信号通路与神经活性配体-受体相互作用、钙、cGMP-PKG、凋亡、雌激素、p53和AGE-RAGE相关。分子对接证实,山茱萸的活性成分(如远藤蟾蜍精和β-谷甾醇)与……、……、……和……进行了合适的对接。山茱萸可能通过多个靶点和通路对抑郁症发挥治疗作用。
本研究阐明,山茱萸通过神经活性配体-受体相互作用和凋亡信号通路抑制……和……的表达,并促进……和……的表达。因此,山茱萸是一种潜在的抑郁症治疗选择,本研究结果将为未来的实验研究提供新的参考点,并为其广泛的临床应用提供科学依据。